Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis

References

• Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology66(11), 1696–1702 (2006).
   PubMed Web of Science ®Google Scholar
• Richards R, Sampson F, Baird S, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment6(10), (2002).
   PubMedGoogle Scholar
• Murphy N, Confavreux C, Haas J et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J. Neurol. Neurosurg. Psychiatry65(4), 460–466 (1998).
   PubMed Web of Science ®Google Scholar
• Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology53(5), 1098–1103 (1999).
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J. Neurol. Sci.218(1–2), 3–7 (2004).
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in MS. Int. MS J.13(1), 17–26, 16 (2006).
   Google Scholar
• Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. A quantitative study of unpaid caregiving in multiple sclerosis. Mult. Scler.6(4), 274–279 (2000).
   PubMed Web of Science ®Google Scholar
• Solari A, Ferrari G, Radice D. A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others. J. Neurol. Sci.243(1–2), 13–20 (2006).
   PubMed Web of Science ®Google Scholar
• Figved N, Myhr KM, Larsen JP, Aarsland D. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J. Neurol. Neurosurg. Psychiatry78(10), 1097–1102 (2007).
   PubMed Web of Science ®Google Scholar
• Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr. Med. Res. Opin.26(1), 109–119 (2010).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33(11), 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Pearson OR, Busse ME, van Deursen RW, Wiles CM. Quantification of walking mobility in neurological disorders. QJM97(8), 463–475 (2004).
   PubMed Web of Science ®Google Scholar
• Rudick R, Antel J, Confavreux C et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann. Neurol.42(3), 379–382 (1997).
   PubMed Web of Science ®Google Scholar
• Fischer J, Jak A, Kniker J, Rudick R, Cutter G. Multiple Sclerosis Functional Composite (MSFC): Administration and Scoring Manual. National Multiple Sclerosis Society, London, UK (2001).
   Google Scholar
• Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet373(9665), 732–738 (2009).
   PubMed Web of Science ®Google Scholar
• Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch. Neurol.57(9), 1319–1324 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS et al. Use of the multiple sclerosis functional composite as an outcome measure in a Phase 3 clinical trial. Arch. Neurol.58(6), 961–967 (2001).
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Mattson DH et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology49(5), 1419–1424 (1997).
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain122(Pt 5), 871–882 (1999).
   PubMed Web of Science ®Google Scholar
• Kalkers NF, de Groot V, Lazeron RH et al. MS functional composite: relation to disease phenotype and disability strata. Neurology54(6), 1233–1239 (2000).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult. Scler.14(5), 679–690 (2008).
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics27(8), 681–691 (2009).
   PubMed Web of Science ®Google Scholar
• Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur. J. Neurol.8(1), 27–35 (2001).
   PubMed Web of Science ®Google Scholar
• Orlewska E, Mierzejewski P, Zaborski J et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur. J. Neurol.12(1), 31–39 (2005).
   PubMed Web of Science ®Google Scholar
• Amato MP, Battaglia MA, Caputo D et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol.249(2), 152–163 (2002).
   PubMed Web of Science ®Google Scholar
• Burden of illness of multiple sclerosis: part I: cost of illness. The Canadian Burden of Illness Study Group. Can. J. Neurol. Sci.25(1), 23–30 (1998).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Smala A et al. Costs and quality of life in multiple sclerosis. Health Economics Prevention Care2, 60–68 (2001).
   Google Scholar
• Kobelt G, Jonsson L, Miltenburger C, Jonsson B. Cost–utility analysis of interferon β-1B in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Health Care18(1), 127–138 (2002).
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler.6(2), 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Henriksson F, Fredrikson S, Jonsson B. Cost–utility analysis of interferon β-1b in secondary progressive multiple sclerosis. Int. J. Technol. Assess. Health Care16(3), 768–780 (2000).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Fredrikson S. Cost–utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur. J. Health Econ.4(1), 50–59 (2003).
   PubMedGoogle Scholar
• Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health Econ.7(Suppl. 2), S75–S85 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur. J. Health Econ.7(Suppl. 2), S55–S64 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur. J. Health Econ.7(Suppl. 2), S45–S54 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P et al. Costs and quality of life of multiple sclerosis in Germany. Eur. J. Health Econ.7(Suppl. 2), S34–S44 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P et al. Costs and quality of life of multiple sclerosis in Spain. Eur. J. Health Econ.7(Suppl. 2), S65–S74 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P et al. Costs and quality of life of multiple sclerosis in Austria. Eur. J. Health Econ.7(Suppl. 2), S14–S23 (2006).
   PubMedGoogle Scholar
• Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur. J. Health Econ.7(Suppl. 2), S24–S33 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur. J. Health Econ.7(Suppl. 2), S86–S95 (2006).
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur. J. Health Econ.7(Suppl. 2), S96–S104 (2006).
   PubMedGoogle Scholar
• Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J. Neurol.255(9), 1354–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Brazier J. The SF-36 health survey questionnaire – a tool for economists. Health Econ.2(3), 213–215 (1993).
   PubMedGoogle Scholar
• Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon β: an appraisal of cost–effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatry68(2), 144–149 (2000).
   PubMed Web of Science ®Google Scholar
• Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes (Second Edition). Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Busche KD, Fisk JD, Murray TJ, Metz LM. Short term predictors of unemployment in multiple sclerosis patients. Can. J. Neurol. Sci.30(2), 137–142 (2003).
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost–effectiveness of interferon β-1a, interferon β-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health7(5), 554–568 (2004).
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost–effectiveness of four immunomodulatory therapies for relapsing–remitting multiple sclerosis: a Markov model based on long-term clinical data. J. Manag. Care Pharm.13(3), 245–261 (2007).
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Hutton J. Cost–effectiveness analysis of interferon β in multiple sclerosis: a Markov process analysis. Value Health5(1), 44–54 (2002).
   PubMed Web of Science ®Google Scholar
• Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J. Neurol. Neurosurg. Psychiatry76(1), 58–63 (2005).
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health10(1), 54–60 (2007).
   PubMed Web of Science ®Google Scholar
• Corrigan R, McBurney H. Community ambulation: environmental impacts and assessment inadequacies. Disabil. Rehabil.30(19), 1411–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Lord SE, McPherson K, McNaughton HK, Rochester L, Weatherall M. Community ambulation after stroke: how important and obtainable is it and what measures appear predictive? Arch. Phys. Med. Rehabil.85(2), 234–239 (2004).
   PubMed Web of Science ®Google Scholar
• Schmid A, Duncan PW, Studenski S et al. Improvements in speed-based gait classifications are meaningful. Stroke38(7), 2096–2100 (2007).
   PubMed Web of Science ®Google Scholar
• Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the stroke population. Stroke26(6), 982–989 (1995).
   PubMed Web of Science ®Google Scholar
• Hill K, Ellis P, Bernhardt J, Maggs P, Hull S. Balance and mobility outcomes for stroke patients: a comprehensive audit. Aust. J. Physiother.43(3), 173–180 (1997).
   PubMedGoogle Scholar
• Robinett CS, Vondran MA. Functional ambulation velocity and distance requirements in rural and urban communities. A clinical report. Phys. Ther.68(9), 1371–1373 (1988).
   PubMed Web of Science ®Google Scholar
• Lernier-Frankiel M, Vargas S, Brown M, Krusell L, Schoneberger W. Functional community ambulation: what are your criteria? Clin. Manag. Phys. Ther.6, 12–15 (1986).
   Web of Science ®Google Scholar
• Lord SE, Rochester L. Measurement of community ambulation after stroke: current status and future developments. Stroke36(7), 1457–1461 (2005).
   PubMed Web of Science ®Google Scholar